FT-2102 (olutasidenib)

allosteric mutant-selective IDH1 inhibitor

oral, in clinical development

from SBDD of prior mIDH inhibitor

J. Med. Chem. 2020, 63, 1612-1623

FORMA Therapeutics, Watertown, MA

FT-2102 (olutsidenib) (FORMA oral allosteric mutant-selective IDH1 inhibitor clinical candidate)


 this content is exclusive to
Premium members

Unlock this content with a Premium membership to read it now.